Letter: Comment on: Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials—The Underrepresented Role of Baseline Disease Severity
Restricted accessLetterFirst published online March, 2026
Letter: Comment on: Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials—The Underrepresented Role of Baseline Disease Severity
ShangW, WangG, HanD. Benefits of nanocurcumin on mortality in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J Integr Complement Med, 2026; 32(1):40–46; doi: 10.1177/27683605251379004
2.
HanH, MaQ, LiC, et al.Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect, 2020; 9(1):1123–1130; doi: 10.1080/22221751.2020.1770129
3.
Del ValleDM, Kim-SchulzeS, HuangHH, et al.An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med, 2020; 26(10):1636–1643; doi: 10.1038/s41591-020-1051-9
4.
ZhaoY, QinL, ZhangP, et al.Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight, 2020; 5(13):e139834; doi: 10.1172/jci.insight.139834
5.
AgarwalA, HuntB, StegemannM, et al.A living WHO guideline on drugs for covid-19. BMJ, 2020; 370(m3379):m3379; doi: 10.1136/bmj.m3379
